Institution
Université Bordeaux Segalen
About: Université Bordeaux Segalen is a based out in . It is known for research contribution in the topics: Population & Cancer. The organization has 1662 authors who have published 1293 publications receiving 37868 citations.
Topics: Population, Cancer, Cohort, Unfolded protein response, Transplantation
Papers published on a yearly basis
Papers
More filters
Food and Drug Administration1, Université Bordeaux Segalen2, Edinburgh Cancer Research Centre3, MedStar Washington Hospital Center4, European Organisation for Research and Treatment of Cancer5, Memorial Sloan Kettering Cancer Center6, University of North Carolina at Chapel Hill7, University of Texas MD Anderson Cancer Center8, Virginia Commonwealth University9, Ludwig Maximilian University of Munich10
TL;DR: In this paper, the authors compared the three most commonly used definitions of pathological complete response (ypT0 ypN0, ypT0/is ypNs0, and ypTsN0/IsYPN0) for their association with EFS and overall survival in clinical trials of neoadjuvant treatment of breast cancer.
2,793 citations
TL;DR: In this 4th edition of the Maastricht consensus report aspects related to the clinical role of H pylori were looked at again in 2010, with recommendations to guide doctors involved in the management of this infection associated with various clinical conditions.
Abstract: Management of Helicobacter pylori infection is evolving and in this 4th edition of the Maastricht consensus report aspects related to the clinical role of H pylori were looked at again in 2010. In the 4th Maastricht/Florence Consensus Conference 44 experts from 24 countries took active part and examined key clinical aspects in three subdivided workshops: (1) Indications and contraindications for diagnosis and treatment, focusing on dyspepsia, non-steroidal anti-inflammatory drugs or aspirin use, gastro-oesophageal reflux disease and extraintestinal manifestations of the infection. (2) Diagnostic tests and treatment of infection. (3) Prevention of gastric cancer and other complications. The results of the individual workshops were submitted to a final consensus voting to all participants. Recommendations are provided on the basis of the best current evidence and plausibility to guide doctors involved in the management of this infection associated with various clinical conditions.
2,167 citations
TL;DR: It is hypothesised that the substantially reduced rates of liver disease and cardiovascular disease deaths over time could be explained by improved use of non-HIV-specific preventive interventions, linked with continued improvement in CD4 cell count.
772 citations
TL;DR: The problem of competing risks in survival analysis is explained and how using different techniques may affect study results is explained.
Abstract: Survival analyses are commonly applied to study death or other events of interest. In such analyses, so-called competing risks may form an important problem. A competing risk is an event that either hinders the observation of the event of interest or modifies the chance that this event occurs. For example, when studying death on dialysis, receiving a kidney transplant is an event that competes with the event of interest. Conventional methods for survival analysis ignoring the competing event(s), such as the Kaplan–Meier method and standard Cox proportional hazards regression, may be inappropriate in the presence of competing risks, and alternative methods specifically designed for analysing competing risks data should then be applied. This problem deserves more attention in nephrology research and in the current article, we therefore explain the problem of competing risks in survival analysis and how using different techniques may affect study results.
506 citations
University of Bordeaux1, University of Paris2, Université Bordeaux Segalen3, University of Rouen4, University of Paris-Sud5, University of Barcelona6, Université catholique de Louvain7, Katholieke Universiteit Leuven8, University of Helsinki9, Helsinki University Central Hospital10, Autonomous University of Madrid11, Ghent University Hospital12, Université libre de Bruxelles13, Paris Diderot University14
TL;DR: Ciclosporin was not more effective than infliximab in patients with acute severe ulcerative colitis refractory to intravenous steroids and should be guided by physician and centre experience.
482 citations
Authors
Showing all 1662 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Michel Haïssaguerre | 117 | 757 | 62284 |
| Jean-François Dartigues | 106 | 631 | 46682 |
| Mélèze Hocini | 89 | 477 | 30883 |
| Bernard Mazoyer | 89 | 337 | 38120 |
| François Dabis | 85 | 571 | 27110 |
| Francis Mégraud | 85 | 495 | 33445 |
| Tobias Kurth | 85 | 428 | 26428 |
| Geneviève Chêne | 77 | 460 | 22654 |
| Annick Alpérovitch | 77 | 240 | 23767 |
| Giovanni Marsicano | 76 | 214 | 21433 |
| Paulette Bioulac-Sage | 67 | 335 | 22739 |
| Carole Dufouil | 67 | 167 | 20686 |
| Didier Lacombe | 63 | 347 | 15739 |
| Nicholas Moore | 63 | 516 | 15476 |
| Ruben Coronel | 61 | 274 | 11868 |